Abstract 2092P
Background
Breast cancer tops the list of cancer types prevalent in Algeria, with more than 14,000 new cases recorded each year, of which a significant rate appears before the age of 40. it is aggressive and requires the use of chemotherapy known to be associated with immediate and long-term toxicities, which may affect the quality of life of cancer survivors. One of the chemotherapy-related long-term toxicities among premenopausal patients is hormonal changes with ovarian failure, chemotherapy-related amenorrhoea (CRA) and early menopause witch may lead to bone loss.The objectives were to evaluate bone mineral density (BMD) and to determine potential associated factors for bone loss among young premenopausal patients after adjuvant chemotherapy.
Methods
We included premenopausal Algerian aged <45 years who had received adjuvant chemotherapy. At study entry, background demographics, cancer characteristics and menstrual history were collected; BMD was measured by DXA in trabecular and cortical sites. Factors associated with reduced BMD and fracture risk were analyzed.
Results
A total of 83 patients were evaluated.The median age at the time of diagnosis of breast cancer is 37 years old, while the age at entry into the study is 43 years old. The median BMDs for femoral neck (FN) was 1.02 g/cm2 and lumbar spine (LS) 0.95 g/cm2; 37.2% had abnormal Z-scores (defined as ≤–1) and 44.7% had osteopenia/osteoporosis of either FN or LS. On multivariate analyses, factors that were identified correlated with bone loss (low BMD) are: young age at cancer diagnosis (OR [95% CI] = 2.103 [1.091–3.181), low Vitamine D level (OR = 2.254 [1.541–4.637]), low BMI (OR = 2.56 [1.599–2.907]), longer interval since last adjuvant treatment (OR for LS: 2.217 [1.250–4.357]), and having received adjuvant tamoxifen (OR = 1.752 [1.243–3.841]).
Conclusions
This study highlights that bone loss is prevelent condition in early breast cancer survivors who are on or after chemotherapy. About 44.7% of early breast cancer survivors found to have bone loss .To prevent bone fracture; certain factors associated with this condition deserve to be detected and corrected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HCA Hospital University of Algiers Algeria.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06